Streetbeat News

BAYRY

Bayer AG

https://www.bayer.de/

CEO

Werner Baumann

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

6.60

Mkt cap

105B

Volume

59K

High

6.69

P/E Ratio

-9.41

52-wk high

8.58

Low

6.57

Div yield

0.00

52-wk low

4.79

Bayer's stock has risen 24.5% since December 2024, but remains speculative due to high debt and ongoing litigation. 2024 results showed a 2.2% sales decline, with slight growth in Pharmaceuticals and declines in Crop Science and Consumer Health. The 2025 outlook is uncertain, with potential sales growth of 1%. Management is optimistic about a turnaround by 2027.

Portfolio Pulse from

March 20, 2025 | 6:15 am

The FDA has accepted and granted priority review to Bayer's supplemental New Drug Application (sNDA) for Kerendia, aimed at treating a common form of heart failure. This development could potentially expand the drug's market and impact Bayer's financial performance.

Portfolio Pulse from

March 18, 2025 | 6:00 pm

Germany's financial markets watchdog is investigating Bayer for potentially not fairly disclosing plans for a capital increase. This scrutiny could impact investor confidence in Bayer's stock.

Portfolio Pulse from

March 11, 2025 | 3:45 pm

Bayer informed several brokerages about its plan to seek shareholder permission to issue shares a day before the official announcement, leading to a negative impact on its stock price.

Portfolio Pulse from

March 07, 2025 | 9:15 pm

The article compares the performance of Bayer Aktiengesellschaft (BAYRY) and AbbVie (ABBV) against their sector in the medical stocks category for the current year.

Portfolio Pulse from

March 07, 2025 | 4:00 pm

Bayer AG has warned US lawmakers it may stop selling its Roundup weedkiller in the US unless stronger legal protections are provided to shield the company from product liability lawsuits. Bayer has already paid $10 billion to settle claims related to Roundup's alleged cancer risks.

Portfolio Pulse from

March 07, 2025 | 3:00 pm

Bayer plans to seek shareholder approval to raise equity capital equivalent to 35% of its current shares over the next three years to prepare for potential U.S. litigation settlements.

Portfolio Pulse from

March 07, 2025 | 12:00 pm

Bayer's fourth-quarter earnings met expectations, while revenues exceeded estimates due to strong sales of its pharmaceutical products, Nubeqa and Kerendia.

Portfolio Pulse from

March 05, 2025 | 9:15 pm

Bayer anticipates a return to earnings growth in 2026 after experiencing a profit decline this year.

Portfolio Pulse from

March 05, 2025 | 7:00 am

Alanna Morris-Simon from Bayer discusses key risk factors for heart disease and shares tips for improving heart health during American Heart Month.

Portfolio Pulse from

February 27, 2025 | 5:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.